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Phosphodiesterase type 5 Inhibitors, such as sildenafil, vardenafil and tadalafil have been 
increasingly used today and some of the users have developed sudden sensorineural hearing loss.
Objective: To present two patients with sudden deafness developed after an occasional use 
of the drug and review studies on the use of phosphodiesterase type 5 inhibitors and sudden 
hearing loss.
Method: Analytical study of two cases and review of the subject matter in the Pubmed/Medline 
and Bireme databases using the keywords: phosphodiesterase type 5 inhibitors and sudden 
deafness and its correlates in the English language.
Results: The patients analyzed are young without additional disorders, using phosphodiesterase 
type 5 inhibitors, and after combination treatment for sudden hearing loss only one had hearing 
improvement. We found nine scientific studies and reviewed preclinical studies, clinical trials, 
prospective and cross-sectional investigations.
Conclusion: Increased occurrence in clinical practice and scientific reports in the literature 
suggest that the phosphodiesterase type 5 inhibitors are considered a risk factor for sudden 
deafness. Further studies with larger samples and control groups are needed for better assessing 
this association.
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INTRODUCTION
Ototoxic drugs may cause balance and hearing di-
sorders, modifying cochlear and vestibular functions. The 
most common known ototoxic drugs are aminoglycoside 
antibiotics; antineoplastic agents, particularly platinum-
-based (cisplatin and carboplatin); as well as some loop 
diuretics: furosemide, salicylic acid and quinine1.
In the first case report associating the use of 
phosphodiesterase type 5 inhibitor (PDE5i) with hearing 
loss in 2007, the authors attributed this disorder to a 
probable ototoxic effect of the drug used (sildenafil) 
and pointed out that there is an extensive list of ototoxic 
drugs such as aminoglycosides, antibiotics and other 
medications, and that was the first case correlating the 
use of sildenafil and sudden-onset hearing loss2.
Phosphodiesterase type 5 inhibitors (PDE5i) such as 
sildenafil, vardenafil and tadalafil are drugs used to treat 
erectile dysfunction, but sildenafil is also indicated for 
pulmonary hypertension. Common adverse effects include 
headache, facial flushing, nasal congestion, dyspepsia and 
nausea. Recently, PDE5i have been associated with adverse 
effects involving vision, and there is emerging evidence 
suggesting that such drugs can be also responsible for he-
aring disorders, increasing the risk of sudden hearing loss3.
Recent concerns about this class of drugs and the 
emergence of cases of sudden sensorineural hearing loss 
(SSNHL) resulted in a requirement of the FDA (Food and 
Drug Administration) - U.S agency that regulates food and 
pharmaceutical products - for a more rigorous labeling. 
Based on these reports, researchers stressed the need to 
investigate the potential relationship between sudden 
sensorineural hearing loss and use of this class of drugs4.
Such drugs are commercially known as silde-
nafil citrate (Viagra® and Revatio®, Pfizer), vardena-
fil (Levitra®, distributed by Bayer Pharmaceuticals, 
Schering-Plough and GlaxoSmithKline), and tadalafil 
(Cialis®, Eli Lilly). Sildenafil was the first PDE5i licensed 
for erectile dysfunction treatment and has been widely 
prescribed since it was FDA-approved in the United 
States5. Though used intermittently, sometimes sildenafil 
must be taken continuously and in large doses. The 
recommended dose of sildenafil citrate for the treatment 
of erectile dysfunction is 25-100 mg per day6.
Sudden deafness is characterized as a senso-
rineural hearing loss of sudden onset and unknown 
cause. There may be inner ear and/or central auditory 
pathways involvement, of variable intensity and fre-
quency, ranging from a mild feeling of stuffed ear, total 
hearing loss, and tinnitus in approximately 80% of the 
cases7-9. Tinnitus may vary in intensity and occurs in 
70% of the cases, and it may recede or persist longer 
than the hearing loss10.
The hearing loss sensation can range from mild 
to very severe, and it may yield to spontaneous recovery 
in 25% or more cases. Sudden hearing loss progression 
behavior is quite variable, with total or partial spontaneous 
recovery; and it may leave irreversible auditory sequelae7.
In a histopathological study of the temporal bone, 
after an episode of sudden hearing loss, there was great loss 
of cochlear neurons, and the organ of Corti and outer hair 
cells were missing in most of the cochlear basal turn, justi-
fying, in that case, the hearing loss in the high frequencies11.
Recent evidence has suggested that phospho-
diesterase type 5 inhibitors may be responsible for 
sensorineural hearing loss of sudden onset2,3,6.
Given the relevance of the proposed topic and 
the fact that there are no publications in Portuguese, we 
became interested in carrying out this study, in order to 
present two cases of patients with sudden sensorineural 
hearing loss who were using phosphodiesterase type 5 
inhibitors, and revisit studies on this correlation.
METHOD
We carried out an analytical study of two ca-
ses of young patients without other disorders, who 
were using phosphodiesterase type 5 inhibitors and 
developed sudden sensorineural hearing loss without 
hearing improvement after combination therapy (oral 
steroids - OS and intratympanic steroid injection ITS), 
for hearing and tinnitus. Patients signed an informed 
consent form (ICF) and the study was approved by the 
Research Ethics Committee of the University of Brasília 
(UNB), under protocol number 132/12.
The search strategy employed in the literature 
review was guided using the keywords indexed in DecS 
(Descriptors in Health Sciences) in Portuguese and in 
MeSH (Medical Subject Headings) in English: sudden 
hearing loss and phosphodiesterase inhibitors and their 
correlates in English: sudden deafness and phospho-
diesterase inhibitors. For this, we used the PubMed and 
Bireme/MedLine databases, and analyzed all papers 
published in indexed journals, including preclinical, 
clinical, prospective and cross-sectional studies.
In this study, we considered only those papers 
published from 1998 to June 2013, a total of 15 years, 
and the last manual search conducted in electronic 
databases occurred in June 2013.
RESULTS
For the two cases presented, Patient 1, aged 37, 
sought medical attention as soon as his mild vertigo and 
hearing loss symptoms started, and he was immediate-
ly subjected to treatment with the use of combination 
729
Brazilian Journal of otorhinolaryngology 79 (6) novemBer/DecemBer 2013
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
therapy for sudden hearing loss, that is, oral corticos-
teroids (OS - prednisolone, 1 mg/kg/day for 10 days 
with a reduction of 10 mg every two days) associated 
with intratympanic steroid injection three times every 
other day (ITS - Methylprednisolone 0.7 ml of a 40 
mg/ml solution, Solumedrol®), and the treatment was 
uneventful.
In the first pure tone audiometry the patient did 
not have hearing thresholds in the left ear. He was 
also submitted to laboratory tests and MRI. He was 
submitted to distortion products evoked otoacoustic 
emissions and auditory evoked potential tests, and had 
results consistent with profound sensorineural hearing 
loss, or no response. There was no improvement even 
after combined therapy (OS + ITS) in audiometric tests 
performed one month after treatment.
Patient 2, aged 43, presented hearing loss, 
tinnitus and severe vertigo as initial symptoms. He 
was submitted to laboratory tests and MRI, as well 
as hearing assessment by pure tone audiometry, 
otoacoustic emissions and Evoked Auditory Brains-
tem Response, with improvements in his hearing 
thresholds.
On tinnitus, we used the Visual Analogue Sca-
le (VAS) for discomfort and intensity as a subjective 
assessment and there was an improvement in score 
(Table 1); Patient 1, being classified as severe to mo-
derate after combined therapy and Patient 2 being 
moderate to mild after therapy. In the Tinnitus Han-
dicap Inventory (THI), we noticed that Patient 1 had 
a change in category, from catastrophic to severe; and 
Patient 2 obtained improvement in score, moving from 
severe to mild (Table 2).
Table 1. Description of the two patients using phosphodiesterase type 5 inhibitors who developed sudden hearing loss.
SPL: Sound pressure level; VAS : Visual Analogue Scale - Intensity of Tinnitus - 0-2: Mild; 3-7: Moderate; 8-10: Severe.
Age (years) Gender Treatment employed
Hearing 
thresholds 
before the 
Treatment 
(Mean 
Tritonal)
Hearing 
thresholds after 
the Treatment 
(Mean Tritonal)
Vertigo 
associated 
with SNHLSO 
before 
combined 
treatment
Vertigo 
associated 
with SNHLSO 
after 
combined 
treatment
Tinnitus before 
combined 
treatment 
(EVA)
Tinnitus after 
combined 
treatment 
(EVA)
Patient 1 37 M OS + ITS
> 110 dB 
SPL > 110 dB SPL
Yes No 10 (Intense) 07 (Moderate)Profound 
sensorineural 
hearing loss
Profound 
sensorineural 
hearing loss
Patient 2 43 M OS + ITS
85 dB SPL 27 dB SPL
Yes No 07 (Moderate) 02 (Mild)Severe 
sensorineural 
hearing loss
Mild 
sensorineural 
hearing loss
Level 1 (score 0-15 - discreet); Level 2 (score 18-36 - mild); Level 3 
(score 38-56 - moderate); Level 4 (score 58-76 - severe); Grade 5 ( 
score 78-100 - catastrophic).
Table 2. Description of the results obtained in the Tinnitus 
Handicap Inventory ( THI ) upon monitoring the patients.
Age 
(years)
Before 
combined 
treatment
1st week 
after 
combined 
treatment
1st month 
after 
combined 
treatment
Patient 1 37
96 (level 5) 64 (level 4) 60 (level 4)
catastrophic severe severe
Patient 2 43
58 (level 4) 36 (level 2) 30 (level 4)
severe severe mild
We found nine papers. The first publication 
correlating the use of phosphodiesterase type 5 and 
sudden hearing loss is from 2007 (Chart 1).
DISCUSSION
The effects of phosphodiesterase type 5 inhibitors 
in the cochlea are still uncertain due to the need for 
more studies with larger groups and a control group, 
and there is a need for otolaryngologists to add to their 
anamneses the possibility that patients with this type of 
hearing loss may be using this class of drugs, since there 
has been some evidence indicating that these drugs may 
be responsible for sudden sensorineural hearing loss.
We also report that it is of fundamental impor-
tance to assess the mechanism of action of these drugs, 
to explain the possible causal association between their 
use and sensorineural hearing loss development, that 
even after the use of combination therapy (oral steroids 
and intratympanic injections), has been irreversible.
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Chart 1. Studies correlating the use of phosphodiesterase type 5 and sudden sensorineural hearing loss.
PTA: Pure tone audiometry; DPEOAE/TEOAE: Distortion Product Evoked Otoacoustic Emissions/Transient evoked otoacoustic emissions; 
ABR: Auditory Brainstem Response, NA: Not applicable.
Study site and year Author Study type Population Assessment method
PTA
TEOAE/
ABR
DPEOAE
2007 Mukherjee & 
Shivakumar2 Case study 44-year-old man X X XIndia
2008
Hong et al.6 Experimental study Albino guinea pigs X XSouth Korea
2009
Maddox et al.4 Case study and review 25 men NA NA NA
USA
2009 Okuyucu et 
al.12 Prospective observational study 18 men XTurkey
2010
McGwin13 Cross-sectional cohort (Epidemiological) 11,525 men NA NA NA
USA
2010 Snodgrass et 
al.3 Case study 57-year old man XUSA
2011
Khan et al.14 Review 47 men NA NA NA
United Kingdom
2012
Bakir et al.15 Experimental study Albino guinea pigs XTurkey
2013
Thakur et al.16 Prospective observational study 25 men X X
India
Based on these results, we notice that in the two 
cases described, the sudden sensorineural hearing loss 
was unilateral, accompanied by tinnitus and dizziness. 
Patient 1 had hearing loss in all frequencies tested, and 
patient 2 had greater hearing loss in the higher frequen-
cies. These findings are consistent with the literature, as 
described in a histopathological study of the temporal 
bone, after an episode of sudden idiopathic hearing 
loss, which revealed a large loss of cochlear neurons, 
mainly in the basal turn of the cochlea, explaining the 
hearing loss in the high frequencies11.
Tinnitus represents a common complaint, perhaps 
the one most often associated with sudden hearing loss7-
9, and we demonstrated that the patients described in 
this study had this symptom. It is important to notice 
that, despite the lack of improvement in the hearing 
thresholds of Patient 1 after combination treatment, 
there was some improvement vis-à-vis the intensity and 
discomfort caused by tinnitus (Tables 1 and 2), which 
reinforces the hypothesis that the tinnitus can recede 
or persist for longer than the hearing loss10.
Patient 2 showed a significant change in hearing 
thresholds, given that his severe hearing loss changed to 
mild after combined treatment, and so had the tinnitus, 
it was severe and went on to be mild (Tables 1 and 2). 
These results observed in Patient 2 were probably due 
to hearing improvement, emotional stabilization and 
habituation to tinnitus.
Given the fact that the clinical history of pa-
tients did not mention comorbidities and, still, that 
sudden hearing loss can be idiopathic, it was possible 
to hypothesize that the use of phosphodiesterase type 
5 inhibitors may have contributed to such occurrence, 
and recent studies have shown such correlation2,4,5,14.
It is of concern that young men, 37 and 43 years 
without other disease, using phosphodiesterase type 5 
inhibitors have had this type of hearing loss, reinforcing 
the possible ototoxicity of this class of drugs and, in 
some cases, the irreversible hearing loss.
Regarding the studies published on this subject, 
the first case report of the use of sildenafil and sudden 
hearing loss in the literature was published in 2007 by 
researchers from India. According to the authors, silde-
nafil is effective for oral treatment of erectile dysfunction 
syndrome and has been broadly used in view of relati-
vely easy availability of such medications, including the 
fact that it can be acquired from the Internet. However, 
the authors emphasized that many patients are not 
aware of the harmful effects of sildenafil and use the 
drug without medical supervision. The case described 
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is of a 44-year-old male patient, who had bilateral pro-
found sensorineural hearing loss, which occurred after 
ingestion of 50 mg/day of sildenafil for 15 days. The 
patient reported that after 15 days of drug administra-
tion, he noticed hearing loss in the right ear and after 
two days of this initial symptom, the same occurred 
to the left ear. The patient was treated with 1mg/Kg/
day of prednisolone for a month and his hearing data 
was documented by means of pure tone audiometry, 
Distortion Product Evoked Otoacoustic Emission and 
Auditory Brainstem Response (ABR)2.
Still in 2007, after this case report, the FDA an-
nounced 113 hearing loss reports from patients who 
used PDE5i, and 84 of these cases were excluded from 
the number of cases for several reasons. The remaining 
29 reports had a strong association between the use 
of PDE5 inhibitors (sildenafil, vardenafil, tadalafil) and 
sensorineural hearing loss. Besides hearing loss, there 
were still reports of tinnitus and dizziness. Given this, 
the FDA required manufacturers of these drugs to alert 
consumers about this possibility: sudden sensorineural 
hearing loss5.
The first experimental study was conducted in 
South Korea in 2008, in which the authors examined 
the hearing of lab animals that received high doses of 
sildenafil for 105 days and the rats were evaluated at 
baseline (0), on the fifth day (5), fifteenth (15), in the 
twenty-fifth day (25), in the thirty-fifth day (35) and the 
hundredth-and-fifth day (105). To assess the hearing, 
the authors used the Auditory Brainstem Response 
(ABR); middle latency auditory responses, as well as 
the evoked otoacoustic emissions. The authors reported 
that, in high doses, sildenafil caused changes to audi-
tory evoked potentials, because it increased the latency 
duration of short latency potentials. The same kind 
of result occurred with the middle latency potentials. 
Otoacoustic emissions differ between the groups of 
high-dose sildenafil and the control group with long-
-term treatment. The authors stated that these results 
indicated a decrease in the number of outer hair cells 
of the organ of Corti and that the probable cause of 
this is the toxic effect due to excess nitric oxide in the 
auditory organs such as the cochlea and the auditory 
nerve. Based on these results, the authors demonstrated 
that the administration of large doses of sildenafil in 
the long term, may contribute to the development of 
sensorineural hearing loss6.
In 2009 , two more cases were reported and there 
was also a review of post-marketing data from the FDA, 
through a retrospective analysis and found the following 
results: of 25 patients analyzed, 15 (88%) had hearing 
loss within 24 hours after taking PDE5 inhibitor. Eight 
patients (32%) reported dizziness associated with hea-
ring loss. In 96% of reported cases, the hearing loss was 
unilateral. Complete hearing recovery was observed in 
five patients (20%), while the other three patients (12%) 
had at least a partial improvement. Therefore, of the 
15 patients with initial hearing loss, only eight patients 
(32%) reported improvement compared to the initial 
complaint. The authors concluded that, although the 
data was not conclusive, there seems to be a potential 
link between the use of PDE5 inhibitor and sudden sen-
sorineural hearing loss. Thus, the authors stressed that 
otolaryngologists should include it in their anamneses 
and among possible causes of sudden sensorineural 
hearing loss, an inquire about the use of any of the 
PDE-5 inhibitors. Although there is currently no direct 
evidence of a mechanism behind this side effect, the 
authors postulated that it is related to the prolonged 
effects of cyclic guanosine monophosphate (GMPc) 
within the cochlea4.
In 2009, the first prospective observational study 
was carried out in humans. Eighteen patients who were 
using a PDE5 inhibitor for erectile dysfunction treatment 
were studied. Threshold Audiometry was performed 
in all patients at frequencies from 250 to 16,000 Hz 
before and after 1, 5 and 72 hours after ingestion of 10 
mg of vardenafil. Four patients showed a statistically 
significant increase in the hearing threshold in one 
ear, consistent with the criteria of ototoxicity within 72 
hours of ingestion of the drug. Furthermore, all patients 
showed a significant unilateral decrease in the threshold 
at 10,000 Hz. However, with the discontinuation of the 
drug, there was improvement in hearing thresholds and 
all the hearing loss disappeared12.
In an epidemiological study carried out in 2010, 
the researcher compared subjects with and without 
hearing loss, who were using the PDE5i. The author 
points out that this was the first epidemiological study 
that evaluated the association between the use of PDE5 
inhibitors and sensorineural hearing loss. The cohort 
consisted of 11,525 men aged 40 years or older and 
chosen from the Medical Expenditure Panel Survey 
between 2003 and 2006. During a period of two years, 
participants provided data in five interviews about their 
demographic information, health, healthy postures 
and drug prescription. They also reported no difficulty 
hearing or the use of hearing aids. The results showed 
that the incidence of hearing loss was 17.9% - a per-
centage which increased with age. Approximately 2% 
of the patients had taken some kind PDE5i, and 80.3% 
of them used sildenafil (Viagra).
The results showed that the hearing loss was 
twice as common among those who made use of PDE5 
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inhibitors (3.0% versus 1.4%). No significant hearing 
loss was seen with tadalafil or vardenafil. However, the 
author attributed this result to the fact that the limited 
use of tadalafil and vardenafil by the participants may 
have limited their ability to find a possible association 
with hearing impairment. The author also highlighted 
that the relationship between the use of PDE5i and 
hearing loss can result from a tendency of drugs that 
promote the congestion of nasal erectile tissue, raising 
middle ear pressure, as well as concerns that PDE5i 
works by blocking cGMP breakdown and its buildup 
induces gene expression through transcription factor 
protein phosphorylation by specific kinases, which 
have been associated with damage to the hair cells 
of the cochlea. Finally, the author points out that the 
irreversible nature of hearing loss and its impact on 
quality of life underscores the need for more research 
on the etiological role of PDE5i use, and because it 
was a cross-sectional study, it provides only a limited 
view on the relationship between the use of PDE5i 
and hearing loss; and therefore requiring further in-
vestigation13.
In 2010 there was a report on a patient who 
developed unilateral sensorineural hearing loss of 
sudden onset, possibly related to the use of vardenafil 
for erectile dysfunction treatment. They described their 
case study as a patient of 57 years who came to the ER 
with hearing loss from mild to moderate in the right 
ear, in the range 500-3000 Hz, confirmed by pure tone 
audiometry and occurred after ingestion of vardenafil. 
The authors described that such patient was hospitali-
zed two days later for the administration of intravenous 
dexamethasone, followed by oral prednisone and an 
improvement in hearing occurred on the fourth day 
of hospitalization and he was discharged three days 
later, continuing prednisone in an outpatient basis. 
Audiometry performed 10 days after treatment with 
corticosteroids, confirmed that the hearing in the range 
of 500-3000 Hz was within normal limits.
The authors considered that there was a possible 
association of sudden sensorineural hearing loss asso-
ciated with the consumption of vardenafil. The authors 
also undertook an analysis of cases of hearing loss as-
sociated with PDE5i in the United States with the FDA’s 
Adverse Events Notice System database, to compare the 
characteristics of their patient with those of other cases 
of adverse events reported and based on the temporal 
relationship of sudden sensorineural hearing loss and 
the use of vardenafil by this patient, they propose that 
vardenafil is a probable cause of hearing loss. According 
to the authors, this case provided new evidence that 
the use of PDE5 inhibitor should be considered as a 
possible cause in patients with sensorineural hearing 
loss of sudden onset3.
A study was conducted in 2011 in order to review 
and analyze the current literature on the correlation 
between the use of PDE5i and hearing loss and su-
ggests possible physiological mechanisms, as well as 
investigate the global communication of this side effect. 
The authors pointed out that the use of sildenafil and 
other PDE5i has grown rapidly since its launch in 1998 
and a growing body of evidence indicates significant 
morbidity associated with the side effects brought about 
by this class of drugs vis-à-vis hearing loss.
For this study, pharmaceutics surveillance agencies 
in North America, Europe and Australia were contacted 
and were requested to provide reports of hearing loss 
associated with the use of PDE5i. Thereafter, the reports 
were examined to exclude those for whom there were 
other possible causes to justify the hearing loss. The au-
thors found 47 cases of sensorineural hearing loss with a 
temporal association with the intake of PDE5 inhibitors, 
based on the literature and on data obtained from phar-
maceutic surveillance agencies. Patients had a mean age 
of 56.6 years. Eighty-eight percent of unilateral hearing 
loss were reported with a uniform distribution between 
the left/right sides. Hearing loss occurred within 24 hours 
after ingestion of a PDE5 inhibitor in 66.7% (n = 18) of the 
cases, and the use of sildenafil accounted for over 50% 
of the cases. Given these results, the authors concluded 
that there is growing evidence that PDE5 inhibitors may 
induce sensorineural hearing loss. And on these results, 
there needs to be more awareness of this disabling side 
effect among the health professionals responsible for 
prescribing this medication. The authors also emphasize 
that with the expiration of sildenafil patents between 
2011-2013, generic drugs are more affordable and may 
cause a significant increase in the use of these drugs, 
as well as an increase in the number of sensorineural 
hearing loss cases14.
In Turkey, in 2012, researchers analyzed the 
histopathological effects of sildenafil use in the long 
term on the cochlea in an animal model. For that, the 
authors studied adult male Wistar albino rats. The con-
trol group was fed with a standard laboratory diet. The 
study group received sildenafil 1.5 mg/kg once daily 
orally for 45 days. Each temporal bone was dissected 
and the cochleae were removed en bloc. The rats were 
divided into two experimental groups: Group 1 (n = 
10) was the control group, to which no medication was 
given, and Group 2 (n = 10) received sildenafil. They 
used 50 mg of sildenafil (Viagra tablets, Pfizer), ground 
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into fine powder and dissolved in 0.9% NaCl. The dose 
of sildenafil citrate administered in this study was 1.5 
mg/kg, a dose compatible with the doses normally used 
in humans. Sildenafil therapy was administered orally 
via an orogastric tube, once a day for 45 days, until 
12 hours prior to surgery. To evaluate their hearing, 
the authors used the Transient Evoked Otoacoustic 
Emissions (TEOAE) test. The authors observed that 
the hematoxylin and eosin stain showed no difference 
between the groups. With respect to immunohistoche-
mical analysis, caspase-3 immunostaining was observed 
in the group taking sildenafil. In the control group, the 
caspase 3 immunoreactivity was not observed. Thus, 
the authors concluded that caspase-3 immunostaining 
in the sildenafil group was strongly associated with an 
increase in apoptotic events in the cochlea, and the 
long-term use of sildenafil may cause hearing loss by 
increasing apoptosis15.
In 2013, we performed the first prospective ob-
servational study using tadalafil in the auditory func-
tion, through an objective hearing evaluation. It was a 
prospective observational study in a tertiary hospital. 
Twenty-five patients who had not used tadalafil and 
had erectile dysfunction and pulmonary arterial hyper-
tension underwent pure tone audiometry and Evoked 
Auditory Brainstem Response (ABR) prior to drug the-
rapy, and 3 and 30 days after drug therapy. The authors 
found that 15 patients used 10 mg of tadalafil for erectile 
dysfunction, and 10 patients were taking 20 mg of ta-
dalafil once daily for pulmonary arterial hypertension. 
There was no statistically significant difference in the 
hearing threshold at baseline and at follow-up (p > 0.05). 
However, three patients used 20mg of tadalafil and had 
significant increase in their hearing thresholds in the 
higher frequencies. There was no incidence of sudden 
sensorineural hearing loss in the study group.
The authors stated that this was the first pros-
pective observational study that evaluated the effect of 
tadalafil on the auditory function with objective eviden-
ce. Although they did not find a statistically significant 
result to confirm or refute the association between 
tadalafil and hearing impairment, raising the threshold 
at higher frequencies after the use of tadalafil supports 
the results of previous studies and suggests a possible 
relationship between the two. Finally, the authors sug-
gest that further studies should be conducted with larger 
similar samples to understand the exact impact of type 
5 phosphodiesterase inhibitors on auditory functions16.
CONCLUSION
The increased occurrence of sudden hearing 
loss in patients using PDE5i and scientific reports in 
the literature suggest that the use of phosphodiesterase 
type 5 inhibitors is regarded as a risk factor for hearing, 
indicating the need for further studies on the possible 
ototoxicity of this class of drugs.
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